MA49744A - Méthodes de traitement de l'oesophagite à éosinophiles active - Google Patents

Méthodes de traitement de l'oesophagite à éosinophiles active

Info

Publication number
MA49744A
MA49744A MA049744A MA49744A MA49744A MA 49744 A MA49744 A MA 49744A MA 049744 A MA049744 A MA 049744A MA 49744 A MA49744 A MA 49744A MA 49744 A MA49744 A MA 49744A
Authority
MA
Morocco
Prior art keywords
treatment methods
eosinophilic esophagitis
active eosinophilic
active
esophagitis
Prior art date
Application number
MA049744A
Other languages
English (en)
Inventor
Jennifer D Hamilton
Leda Mannent
Allen Radin
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Publication of MA49744A publication Critical patent/MA49744A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA049744A 2017-08-04 2018-08-03 Méthodes de traitement de l'oesophagite à éosinophiles active MA49744A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762541242P 2017-08-04 2017-08-04
US201762561593P 2017-09-21 2017-09-21
EP18305252 2018-03-08

Publications (1)

Publication Number Publication Date
MA49744A true MA49744A (fr) 2020-06-10

Family

ID=63113646

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049744A MA49744A (fr) 2017-08-04 2018-08-03 Méthodes de traitement de l'oesophagite à éosinophiles active

Country Status (9)

Country Link
EP (1) EP3661551A1 (fr)
JP (2) JP7417515B2 (fr)
KR (1) KR20200035442A (fr)
CN (1) CN111032084A (fr)
AU (1) AU2018311981A1 (fr)
CA (1) CA3071528A1 (fr)
IL (1) IL272245A (fr)
MA (1) MA49744A (fr)
MX (1) MX2020001305A (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023208104A1 (fr) * 2022-04-29 2023-11-02 中山康方生物医药有限公司 Anticorps anti-ra de l'il-4 humaine et son application

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI682781B (zh) * 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
SG11201603127WA (en) * 2013-10-23 2016-05-30 Genentech Inc Methods of diagnosing and treating eosinophilic disorders
BR112017019412A2 (pt) * 2015-03-11 2018-05-02 Glaxosmithkline Ip Dev Ltd proteínas ligadoras de tslp

Also Published As

Publication number Publication date
RU2020109331A (ru) 2021-09-06
CN111032084A (zh) 2020-04-17
MX2020001305A (es) 2020-03-09
RU2020109331A3 (fr) 2021-12-28
JP2020529434A (ja) 2020-10-08
AU2018311981A1 (en) 2020-02-20
IL272245A (en) 2020-03-31
JP2024016237A (ja) 2024-02-06
JP7417515B2 (ja) 2024-01-18
EP3661551A1 (fr) 2020-06-10
KR20200035442A (ko) 2020-04-03
CA3071528A1 (fr) 2019-02-07

Similar Documents

Publication Publication Date Title
MA45192A (fr) Traitement d'association
MA40867A (fr) Méthodes pour le traitement d'infections virales à filoviridae
DK3516060T3 (da) Antisense-oligonukleotider til behandling af øjensygdom
MA46954A (fr) Méthodes de traitement d'états inflammatoires
DK3364997T3 (da) Aspartoacylase genterapi til behandling af canavans sygdom
MA45563A (fr) Méthodes de traitement du cancer de l'ovaire
DK3448999T3 (da) Oligonukleotider til behandling af øjensygdom
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
DK3386511T3 (da) Fremgangsmåder til behandling af huntingtons sygdom
MA41028A (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
MA46062A (fr) Traitement par ascaroside de l'oesophagite à éosinophiles
MA53329A (fr) Méthodes de traitement de l'épilepsie
MA47719A (fr) Esketamine pour le traitement de la dépression
MA47504A (fr) Composés et méthodes de traitement de l'angiocholite biliaire primitive
DK3393579T3 (da) Øjenbehandlingssystem
DK3784103T3 (da) Gulvbehandlingsmaskine
MA52216A (fr) Méthodes de traitement de la colite ulcéreuse
MA46524A (fr) Composés de biphényl-sulfonamide destinés au traitement de néphropathies
ES2893126T8 (es) Métodos de tratamiento de afecciones oculares
MA46353A (fr) Méthodes de traitement de l'infertilité féminine
MA47212A (fr) Méthodes de traitement de troubles neurologiques
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
MA54860A (fr) Méthodes de traitement du myélome multiple
MA47437A (fr) Procédés de traitement d'infections fongiques
IT201700117210A1 (it) Fungicida biologico